Use of proton pump inhibitors in hematopoietic stem cell transplantation does not increase the frequency of febrile neutropenia.
Makaleler > Tam Makale · 2015
Yazarlar: M C Ozkan, Ayhan DÖNMEZ, A Arslan, Sabire Şöhret AYDEMİR, M Tombuloglu
European review for medical and pharmacological sciences, Uluslararası, 2015, cilt 19, ss 4105-10
Özet
OBJECTIVE: Despite the fact that proton pump inhibitor (PPI) use is a risk factor for infections in heterogeneous groups of patients, there are only a limited data related to PPI use and febrile neutropenic episodes (FNEs) in hematopoietic stem cell transplantation (HSCT) patients. PATIENTS AND METHODS: In a 7-year period, we retrospectively reviewed 145 HSCT data to identify a risk factor for PPI use for febrile neutropenia. The follow-up process of 125 (86.2%) of the HSCTs was complicated with FNEs. RESULTS: A multivariate analysis indicated that PPI use was not significantly associated with FNEs (Odds ratio [OR]: 0.46; 95% Confidence Interval [CI] 0.12-2.16; p = 0.24) or bacterial culture positivity (OR: 1.37; 95% CI 0.45-4.18; p = 0.58). CONCLUSIONS: Our study revealed that PPI use does not appear to be a risk factor for FNE or bacterial culture positivity for HSCT patients but further studies are needed.